Literature DB >> 27958295

Haematological cancer: Rituximab enhances responses to lenalidomide.

Peter Sidaway.   

Abstract

Entities:  

Year:  2016        PMID： 27958295     DOI： 10.1038/nrclinonc.2016.210

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma.

Authors:  Barbara Kiesewetter; Ella Willenbacher; Wolfgang Willenbacher; Alexander Egle; Peter Neumeister; Daniela Voskova; Marius Erik Mayerhoefer; Ingrid Simonitsch-Klupp; Thomas Melchardt; Richard Greil; Markus Raderer
Journal:  Blood       Date:  2016-11-22       Impact factor: 22.113
  1 in total
  2 in total

1.  Affinity-Based Polymers Provide Long-Term Immunotherapeutic Drug Delivery Across Particle Size Ranges Optimal for Macrophage Targeting.

Authors:  Nathan A Rohner; Linda N Purdue; Horst A von Recum
Journal:  J Pharm Sci       Date:  2020-10-27       Impact factor: 3.534

Review 2.  Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.

Authors:  Alessandra Zingoni; Cinzia Fionda; Cristiana Borrelli; Marco Cippitelli; Angela Santoni; Alessandra Soriani
Journal:  Front Immunol       Date:  2017-09-25       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.